Acute-on-chronic liver failure(ACLF)is a complex clinical syndrome characterized by high 28-day and 90-day mortality rates,ranging from 13%to 93%,resulting from the acute deterioration of liver function in patients wi...Acute-on-chronic liver failure(ACLF)is a complex clinical syndrome characterized by high 28-day and 90-day mortality rates,ranging from 13%to 93%,resulting from the acute deterioration of liver function in patients with chronic liver disease.Transplantation of umbilical cord-derived mesenchymal stem cells(UC-MSCs)at different cell dosages has been shown to improve hepatic function in patients with decompensated cirrhosis or ACLF.[1,2]Notably,most clinical studies to date have used freshly prepared MSCs.This trial aimed to evaluate the tolerability,safety,and efficiency of off-the-shelf UC-MSC products in patients with ACLF.展开更多
基金supported by grants from the National Key Research and Development Program of China(No.2020YFA0710804)Key Research and Development Program of Shaanxi(No.2023ZDLSF-34)Clinical Research Project of Air Force Military Medical University(Nos.2021LC2105 and 2023LC2311).
文摘Acute-on-chronic liver failure(ACLF)is a complex clinical syndrome characterized by high 28-day and 90-day mortality rates,ranging from 13%to 93%,resulting from the acute deterioration of liver function in patients with chronic liver disease.Transplantation of umbilical cord-derived mesenchymal stem cells(UC-MSCs)at different cell dosages has been shown to improve hepatic function in patients with decompensated cirrhosis or ACLF.[1,2]Notably,most clinical studies to date have used freshly prepared MSCs.This trial aimed to evaluate the tolerability,safety,and efficiency of off-the-shelf UC-MSC products in patients with ACLF.
